Search PubMed⌕ Search

Biomedical subjects

J Sany

Publications and source records attributed to J Sany.

At least 307 records · Page 17Linked to original sources
PubMedDate not supplied

Immunological treatment of rheumatoid arthritis.

Till now the therapeutic immunomodulation of rheumatoid arthritis (RA) has been non-specific, using either slow acting drugs which act mainly but not exclusively on macrophages (gold salts) or on T CD4+ cells (D penicillamine), or immunostimulating agents (Levamisole) or immunodepressive drugs which do not affect a specific subpopulation of lymphocytes. Various other therapeutic approaches such as dietic manipulations, steroid pulses and plasmapheresis have been proposed. Methotrexate is a very interesting development in the treatment of RA. However, the results of such treatments on the long term outcome of the disease have been unsatisfactory. Early and associated treatments must be studied. After the interesting experimental results obtained with thoracic duct drainage, a partially specific immunotherapy acting mainly on CD4+ T cells has been developed using cyclosporin A and total lymphoid irradiation. However, a more specific immunotherapy of RA may be considered, using monoclonal or polyclonal anti-HLA class II antibodies or anti-CD4 monoclonal antibodies. Immunomodulating treatments with cytokines or anticytokines, anti-T receptor monoclonal antibodies, anti-idiotypic antibodies, and vaccination with T cell clones or synthetic peptides are possibilities of major interest for the future.

Animals↗
PubMedDate not supplied

[Immunologic disturbances in psoriatic arthropathy (author's transl)].

It was observed in 51 cases of psoriatic arthropathy (PA) an increase of blood IgA and a decrease of IgM, a not significant rise of the level of circulating immune complexes, a positive Waaler-Rose reaction in 9.7% of cases and the presence of antigammaglobulin factors (generally of IgG type) in 55,5% of studied patients. Moreover, it was noted a significant decrease of T lymphocytes as detected by E and "active" E rosettes, of EA-gamma rosettes (ox erythrocytes) and an increase of the percentage of high avidity Fc-gamma receptor bearing cells. Lymphocytes responses to mitogens were normal or slightly decreased for Concanavalin A. No correlation was found between the immunological data and the clinical features.

Female↗
PubMedDate not supplied

[Cartilage and synovial membrane].

The synovial membrane acts on the cartilage at the levels of the synovial cells, the production of soluble factors and the cartilage components. The synovial membrane is at the same time a trophic, an immunologic and a defense organ. One does not oppose anymore the aspects found in normal synovium to those found in osteoarthritis and in rheumatoid arthritis. Synovial reactivity against the cartilage components is mediated by specific initiating mechanisms leading to an amplification process. Various soluble factors regulate this cooperation at the articular and the systemic levels. The dysregulation between these factors plays a role in the pathogenesis of joint diseases.

Cartilage, Articular↗
PubMedDate not supplied

Immunofixation improves the detection of monoclonal gammopathy of undetermined significance (M.G.U.S.) in patients with rheumatoid arthritis.

Monoclonal gammopathy of undetermined significance (MGUS) was detected by immunofixation (IFX) in 6% of patients with rheumatoid arthritis (RA), whereas it was detected by immunoelectrophoresis in only 1% of these patients. Most of the patients with both RA and MGUS had polyclonal B cell activation, together with their monoclonal band, extra-articular features and long-lasting disease, which suggests a direct relationship between MGUS and RA status.

Arthritis, Rheumatoid↗
PubMedDate not supplied

[Involvement of lymphocyte populations in rheumatoid synovial lesions].

T and B lymphocyte proportions have been studied in synovial fluid and peripheral blood from 70 patients with classical or definite rheumatoid arthritis (RA). The results have shown that T-cell numbers assessed by E-rosettes and anti-HTLA antiserum, B-cell numbers detected by membrane immunofluorescence and EAC-rosettes from peripheral blood were similar in RA and in a control group. Conversely, "active" E-rosettes which detected a subset of mature T cells, were decreased in blood and very increased in synovial fluid. Furthermore, the percentages of mononuclear cells bearing a Fc-receptor for IgG (EA-rosettes) were higher in synovial fluid than in RA peripheral blood. These data could be in favour of the cell-mediated immunity in rheumatoid arthritis lesions.

Arthritis, Rheumatoid↗
PubMedDate not supplied

Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.

Measuring serum beta-2-microglobulin (B2M) in 90 patients with multiple myeloma (MM) from diagnosis to death (83 cases), or to the terminal phase of their disease (7 cases), we have obtained evidence that 9% of them retained normal serum B2M levels during the whole of their follow-up. This was observed in 6 IgA MM, in one light chain MM only and in one non-secretory MM. These data suggest a lack of B2M production and/or secretion by some myeloma tumors. This could limit the use of B2M as clinical marker in MM.

Humans↗
PubMedDate not supplied

[Treatment of rheumatoid polyarthritis with IgG eluted from the placenta. Results of an open study on 31 patients].

Thirty-one patients presenting classical or defined, severe and active rheumatoid polyarthritis (RP) unresolved by most of the usual basic treatments (due to inefficacy or safety problems) were treated with human placental IgG preparations (HPIgG) in an open study. Various therapeutic protocols were tested to determine the most efficacious dosage. Favorable results were noted in 62% of cases. Improvement was generally rapid, often occurring after the first week of treatment. Rheumatoid nodules subsided by more than 50% and were resolved in two of nine cases. A decrease in dosage of analgesics or anti-inflammatories was possible in seven of 31 cases. Remission of RP of duration exceeding six months after withdrawal of HPIgG treatment was noted in six of 18 favorable results (33.3%). Best results were seen with intravenous administration of 1,500 mg per day seven days per month. No clinical or immunological effects were seen in a control group treated with venous globulins (1,500 mg/day for seven days). Safety was very satisfactory: four withdrawals from treatment due to proteinuria (3 cases) or phlebitis (1 case); these adverse reactions subsided rapidly. Immunostimulation of lymphocyte function was seen in all patients treated with HPIgG. The mode of action of HPIgG is currently under study. HPIgG may act as polyspecific antibodies against class II HLA antigens thus opening up the possibility of a new type of therapeutic immunomodulation in man.

Adult↗